In May 2026, At the EASL Congress 2026, MetaVia presented promising late-breaking Phase 1 clinical trial results for DA-1726, an investigational dual GLP-1 and glucagon receptor agonist under development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Final Thoughts The growth-hormone secretagogue class isn't one thing it's at least two distinct mechanisms (GHRH analogs and GHS/ghrelin agonists) that researchers study both individually and, increasingly, in combination
Lisa Hartford, MD The Hero Molecules of At-Home Microinfusion: PDRN, EGF, GHK-Cu, and the Science of Hollow-Needle Serum Delivery Medically reviewed by Dr
Organoids were incubated in Cell Recovery solution (354253) for 30 min at 4 C
But does supplementing with it help to improve our immune function